氨磺必利与氯氮平治疗阴性症状为主精神分裂症患者的临床效果对比

Comparison of the clinical effects of amisulpride and clozapine in the treatment of patients with negative symptoms of schizophrenia

目的分析比较氨磺必利与氯氮平分别治疗阴性症状为主精神分裂症的临床疗效。方法选择衡阳市第二人民医院2017年2月-2018年1月收治的86例阴性症状为主精神分裂症患者,采用随机法分为两组,每组43例。分别采用氨磺必利(实验组)与氯氮平(对照组)治疗,实验疗程结束后比较不同用药方案对患者的疗效与药物安全性。结果治疗12周后实验组精神分裂症患者阴性症状评分比对照组低,生命质量、生活质量评分比对照组高(P<0.05);总有效率实验组(86.05%)与对照组(67.44%)差异明显(P<0.05);不良反应发生率实验组(9.30%)与对照组(25.58%)也有明显差异(P<0.05)。结论相较于氯氮平长期用药,氨磺必利用来治疗阴性症状为主精神分裂症患者的临床疗效更为确切,阴性症状改善更为理想,认为可以优先选择。

Objective To analyze the clinical efficacy of amisulpride and clozapine in the treatment of negative symptoms for schizophrenia. Methods The retrospective method was used to collect the clinical data of 86 schizophrenic patients with negative symp. toms in Hengyang Second People's Hospital from February 2017 to January 2018. They were divided into two groups of 43 cases accord. ing to different medication schemes. Amisulpride (experimental group) and clozapine (control group) were used to treat the patients respectively. After the end of the experimental course, the efficacy and safety of different drug regimens were compared. Results After 12 weeks of treatment, the negative symptom scores of schizophrenia patients in the experimental group were lower than those in the control group, and the scores of quality of life and quality of life were higher than those in the control group (P<0.05);the total effective rate of schizophrenia patients in the experimental group (86.05%) was significantly different from that in the control group (67.44%)(P<0.05);the incidence of adverse reactions in the experimental group (9.30%) was also significantly different from that in the control group (25.58%)(P<0.05). Conclusion Compared with the long-term use of clozapine, amisulpride is better to treat patients with schizo. phrenia with negative symptoms. The clinical effect is more accurate, the improvement of negative symptoms is more ideal, and should be preferred.